Exploring Mitochondrial Nephrotoxicity as a Potential Mechanism of Kidney Dysfunction among HIV-Infected Patients on Highly Active Antiretroviral Therapy

Background Tenofovir (TDF) exposure has been associated with renal dysfunction. Mitochondrial nephrotoxicity was investigated as an underlying mechanism. Given the interaction between TDF and didanosine (ddI), their concurrent use was also investigated. Design Relative kidney biopsy mitochondrial DNA (mtDNA) to nuclear DNA ratios were measured retrospectively. HIV+ individuals on TDF within 6 months preceeding the biopsy (HIV+/TDF+, n=21) were compared to HIV+ individuals who never received TDF (HIV+/TDF-, n=10) and to HIV uninfected controls (HIV–,n=22). Twelve of the HIV+/TDF+ individuals received concurrent ddI, 10 of those once at unadjusted ddI dosage. Tubular mitochondria morphology was also examined by electron microscopy. Statistical analyses were done on log-transformed mtDNA/nDNA, using non-parametric tests. Results Kidney mtDNA levels were different among the three groups (P=0.046). mtDNA ratios were lower in HIV+/TDF+ subjects (7.5 [2.0–12.1]) than in HIV- ones (14.3 [6.0–16.5], P=0.014), but not lower than HIV+/TDF-controls (6.4 [2.8–11.9], P=0.82). Among HIV+ subjects, there was a difference between TDF-, TDF+/ddI- and TDF+/ddI+ (P=0.005), with concurrent TDF/ddI use associated with lower mtDNA (2.1 [1.9–5.5], n=12) than TDF+/ddI- (13.8 [7.5–16.4], n=9, P=0.003). No TDF–/ddI+ biopsies were available. In regression analyses, only HIV infection (P=0.03), and TDF/ddI use (P=0.003) were associated with lower mtDNA. At the ultrastructural level, abnormal tubular mitochondria was more prevalent in HIV+/TDF+ biopsies than HIV+/TDF- and HIV- ones together (P<0.001) but not more so in TDF+/ddI+ biopsies than TDF+/ddI- ones (P=0.67). Conclusions Renal dysfunction in this population may be mediated through mitochondrial nephrotoxicity that involves more than one drug and/or pathogenesis. Kidney mtDNA depletion was associated with HIV infection and concurrent TDF/ddI therapy but not TDF use alone, while kidney ultrastructural mitochondrial abnormalities were seen with TDF use. The interaction between TDF and ddI may be relevant in the kidney where both drugs are cleared. The clinical relevance of our findings needs to be evaluated given the current recommendation for reduced doses of ddI when used in conjunction with TDF.

[1]  H. Harmouche,et al.  Insuffisance rénale aiguë avec diabète insipide et syndrome de fanconi chez un patient infecté par le virus de l'immunodéficience humaine traité par ténofovir , 2005 .

[2]  V. Calvez,et al.  Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[3]  Richard D Moore,et al.  Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  V. Abraira,et al.  High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir , 2005, AIDS.

[5]  J. Gallant,et al.  Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  B. Clotet,et al.  Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine , 2005, AIDS.

[7]  David Nolan,et al.  Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics , 2005, Expert opinion on drug safety.

[8]  U. Walker,et al.  Mitochondrial Toxicity of Nucleoside Analogues in Primary Human Lymphocytes , 2005, Antiviral therapy.

[9]  E. Daugas,et al.  HAART-related nephropathies in HIV-infected patients. , 2005, Kidney international.

[10]  T. Pumarola,et al.  Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine , 2005, AIDS.

[11]  S. Mauss,et al.  Antiretroviral therapy with tenofovir is associated with mild renal dysfunction , 2005, AIDS.

[12]  D. Podzamczer,et al.  Early Virological Failure with a Combination of Tenofovir, Didanosine and Efavirenz , 2005, Antiviral therapy.

[13]  B. Gazzard,et al.  Renal Dysfunction With Tenofovir Disoproxil Fumarate-Containing Highly Active Antiretroviral Therapy Regimens Is Not Observed More Frequently: A Cohort and Case-Control Study , 2004, Journal of acquired immune deficiency syndromes.

[14]  S. Sauleda,et al.  Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? , 2004, AIDS.

[15]  H. B. Fung,et al.  Fatal Lactic Acidosis Associated with Coadministration of Didanosine and Tenofovir Disoproxil Fumarate , 2004, Pharmacotherapy.

[16]  Michael S Saag,et al.  Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .

[17]  Joel E Gallant,et al.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.

[18]  J. Mallolas,et al.  Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine , 2004, Hepatology.

[19]  L. Chauvelot‐Moachon,et al.  Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  B. Day,et al.  Mitochondrial toxicity of nrti antiviral drugs: an integrated cellular perspective , 2003, Nature Reviews Drug Discovery.

[21]  P. Harrigan,et al.  Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens. , 2003, The Journal of infectious diseases.

[22]  M. Perazella,et al.  Drug‐Induced Renal Failure: Update on New Medications and Unique Mechanisms of Nephrotoxicity , 2003, The American journal of the medical sciences.

[23]  S. Chou,et al.  Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  H. Izzedine,et al.  Drug-induced Fanconi's syndrome. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  R. Schooley,et al.  Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study , 2002, AIDS.

[26]  K. Chaloner,et al.  The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial , 2001, AIDS.

[27]  V. D’Agati,et al.  Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. , 2001, Human pathology.

[28]  J. Shaw,et al.  Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.